Processa Pharmaceuticals, Inc. (PCSA)
NASDAQ: PCSA · Real-Time Price · USD
1.110
-0.030 (-2.64%)
Nov 4, 2024, 4:00 PM EST - Market closed

Processa Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2015
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2015
Net Income
-11.53-11.12-27.42-11.43-14.41-3.36
Upgrade
Depreciation & Amortization
000.790.790.80.8
Upgrade
Other Amortization
--0.12-0.20
Upgrade
Asset Writedown & Restructuring Costs
--7.270.38.6-
Upgrade
Stock-Based Compensation
0.731.068.833.412.730.51
Upgrade
Other Operating Activities
0.091.390.27-0.61-0.92-0.53
Upgrade
Change in Accounts Receivable
--0.070.01-0.08-
Upgrade
Change in Accounts Payable
0.37-0.020.11-0.10.25-0.22
Upgrade
Change in Other Net Operating Assets
-0.780.620.36-1.08-0.310.04
Upgrade
Operating Cash Flow
-11.12-8.06-9.61-8.72-3.14-2.75
Upgrade
Capital Expenditures
-0-0----
Upgrade
Investing Cash Flow
-0-0----
Upgrade
Short-Term Debt Issued
----0.70.81
Upgrade
Long-Term Debt Issued
----0.16-
Upgrade
Total Debt Issued
----0.860.81
Upgrade
Net Debt Issued (Repaid)
-0---0.860.81
Upgrade
Issuance of Common Stock
7.186.32-10.0517.10.9
Upgrade
Repurchase of Common Stock
-0.02-0.05-0.39-0.06-0.1-
Upgrade
Other Financing Activities
----0.19--0
Upgrade
Financing Cash Flow
7.166.27-0.399.817.871.7
Upgrade
Net Cash Flow
-3.97-1.8-9.991.0814.72-1.05
Upgrade
Free Cash Flow
-11.12-8.07-9.61-8.72-3.14-2.75
Upgrade
Free Cash Flow Per Share
-4.39-6.15-11.92-11.38-8.38-9.95
Upgrade
Levered Free Cash Flow
-5.52-4.11-2.96-4.19-0.23-1.31
Upgrade
Unlevered Free Cash Flow
-5.52-4.11-3.08-4.19-0.25-1.29
Upgrade
Change in Net Working Capital
0.52-0.680.031.16-0.230.14
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.